Shattuck Labs Phase 1 SL-325 data boosts TL1A/DR3 blockade; Crohn's trial on track
Aug 11, 2026, 6:17 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Clinical progress (Phase 2b start) and strong Phase 1 signals for SL-325, plus SL-846 IND-enabling progress, could drive a re-rating. Cash runway to 2029 reduces dilution risk; multiple upcoming investor events add liquidity and visibility. Historical biotech catalysts around Phase 2b starts commonly produce outsized moves, though execution risk remains.
AI summary
What happened, with direct paths to the underlying reporting
Shattuck Labs reported Q2 2026 results with SL-325 Phase 1 data showing favorable safety, strong immunogenicity profile, and durable TL1A-DR3 blockade, supporting quarterly maintenance dosing. The RECEPTIVE-CD1 Crohn's trial is slated to begin in Q3 2026, while SL-846 data is anticipated in 2027. The company ended the period with $208.3 million in cash and equivalents, providing runway into 2029 and preserving optionality for pipeline expansion.
RECEPTIVE-CD1 Phase 2b Crohn's trial expected to start in Q3 2026 with 232 patients.
SL-846: DR3 x IL-23R bispecific; IND-enabling, phase data expected 2027.
Cash and equivalents/investments: $208.3 million as of 6/30/2026; runway to 2029.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Shattuck Labs reported positive Phase 1 data for SL-325, a DR3-targeting antibody for inflammatory bowel disease, with favorable safety and occupancy supporting a Phase 2b in 3Q20…
HC Wainwright upgraded STTK to Buy with a $6 price forecast. Shattuck's SL-325 targets DR3 for IBD, potentially capturing market share. First healthy participants dosed in Phase 1…
Shattuck Labs discontinued SL-172154 development due to limited efficacy. Stock fell 45% following the announcement, impacting investor confidence. Collaboration with Ono Pharmace…
Shattuck Labs Inc. stock fell 43% after scrapping main product candidate. Company to cut 40% of its staff as part of restructuring. Termination of license agreement with Ono Pharm…
